Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
CAR-CD19 T cell
The First People's Hospital of Lianyungang
B Cell Lymphoma
1 trial -
CD19 CAR T-cell
Universal Integrated
B-cell Acute Lymphoblastic Leukemia
1 trial -
CD19 CAR-T cells infusion
The First People's Hospital of Lianyungang
Non Hodgkin Lymphoma
1 trial -
COVID Convalescent Plasma
Xiyuan Hospital of China Academy of Chinese Medical Sciences
COVID-19
1 trial -
CSB14
United Therapeutics Europe Ltd
Child Malnutrition
1 trial -
CYP2C19 genotype testing
Beijing Anzhen Hospital
Angina, Stable
1 trial -
Calcium Carbonate 1500 Mg with Vitamin D
Hospital Authority, Hong Kong
Thyroid Neoplasm
1 trial -
Capsule 1 or Capsule 2
United Therapeutics Europe Ltd
Pregnancy
1 trial -
Coenzyme Q10
United Therapeutics Europe Ltd
Gulf War Illness
1 trial -
Coenzyme Q10
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cardiovascular Disease
1 trial -
DGB-01 Supplementation
Blackmores Limited
Fatigue
1 trial -
DM199
DiaMedica Therapeutics
Pre-Eclampsia
1 trial -
Diagnostic Test: conventional imaging (CT, MRI or 18F-FDG PET/CT), DLL3-targeted PET/CT
The First People's Hospital of Lianyungang
DLL3-expressing Tumors
1 trial -
ESC 0/1 hour troponin pathway
NORTHWEST BIOTHERAPEUTICS INC
Acute Coronary Syndrome
1 trial -
ET-01
Guangzhou Virotech Pharmaceutical Co.,
Transfusion Dependent Beta-Thalassaemia
1 trial -
ET-01
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Transfusion Dependent Beta-Thalassaemia
1 trial -
ETEC strain B7A (O148:H28 CS6+ LT+ST+) (Lot 0481) in Buffer
United Therapeutics Europe Ltd
Healthy Volunteer
1 trial -
EVM18001 Injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
System Lupus Erythematosus(SLE)
1 trial -
Early auto-mode
Century Therapeutics
Diabetes Mellitus Type 1 Pre-Existing
1 trial -
Efgartigimod + Telitacicept (1-week interval) group
The First People's Hospital of Lianyungang
Myasthenia Gravis
1 trial -
ExoBDNF SWP-CGPA01 (Pediococcus acidilactici)Capsules
Biotech Pharmaceutical Co.,
Cognitive Functions Perceptual Disturbances
1 trial -
FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Biliary Tract Neoplasms
1 trial -
Favipiravir
The First People's Hospital of Lianyungang
COVID-19
1 trial -
Fecal Microbiota Transplantation (FMT)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Type 1 Diabetes
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources